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Streptococcus sinensis has been described as a caus-
ative organism for infective endocarditis in 3 Chinese pa-
tients from Hong Kong. We describe a closely related strain 
in an Italian patient with chronic rheumatic heart disease. 
The case illustrates that S. sinensis is a worldwide emerg-
ing pathogen.
Among the hundreds of bacteria that are pathogenic for humans, some are reposted only once and remain a 
rarity, while others are considered as emerging pathogens 
after several cases have been published. In 2002, Woo et al. 
from Hong Kong Special Administrative Region, People’s 
Republic of China, reported a new pathogen isolated from 
a 42-year-old Chinese woman with mitral regurgitation due 
to chronic rheumatic heart disease and infective endocardi-
tis (HKU4) (1). Its 16S rRNA sequence (2) showed a new 
streptococcal species, subsequently named Streptococcus 
sinensis in honor of China; the sequencing showed that it 
was closely related to Streptococcus gordonii (96.4% ho-
mology) and to Streptococcus intermedius (96.3%) (1). 
Phenotypically, the species most closely resembled S. in-
termedius; some evidence suggests that S. sinensis could 
be the common ancestor of S. anginosus and S. mitis (3). In 
2004, the same group published a retrospective analysis of 
302 bacteremia cases caused by S. viridans in Hong Kong, 
including 2 other cases of endocarditis caused by S. sinen-
sis with Lancefi eld group F (4). We describe another case 
of an infective endocarditis (or infection in general) due to 
S. sinensis outside Hong Kong.
The Case
In December 1998, a 57-year-old Italian man with a 
severe mitral insuffi ciency of rheumatic origin underwent 
a nonbleeding dental procedure without antimicrobial 
prophylaxis. One month later, he was hospitalized at the 
University Hospitals of Geneva with fever (38°C–39°C), 
rigors, and weight loss of 4 kg in 3 weeks. There was no 
history of prior endocarditis, drug abuse, traumatism, or 
concomitant disease. At admission he was hemodynami-
cally compensated and without fever. Over the cardiac 
apex, a grade 5/6 proto-mesosystolic murmur was audible. 
Transesophageal echocardiography showed vegetation on 
the mitral valve without abscesses. An ophthalmologic ex-
amination showed an embolus near the right macula. The 
urinary sediment exhibited microhematuria. In all blood-
culture bottles, a gram-positive Streptococcus sp. was 
grown. Thus, infective endocarditis was diagnosed by the 
presence of 2 major and 3 minor criteria according to modi-
fi ed Duke criteria (5).
An antimicrobial drug treatment with intravenous (i.v.) 
penicillin G 6 × 4 million U/day and gentamicin 3 × 1 mg/
kg/day for 3 weeks was initiated. After an excellent clinical 
course and normalization of infl ammation markers, treat-
ment was switched to i.v. ceftriaxone 1 × 2 g/day for anoth-
er 3 weeks to enable outpatient therapy (6). No secondary 
abscesses occurred. Several infected teeth were extracted 
during treatment. Because of the severity of the preexist-
ing mitral regurgitation, an elective replacement with a 
mechanical prosthesis was performed in March 1999. The 
patient was considered cured. Three years later he died 
of cerebral hematoma attributed to oral anticoagulation. 
Autopsy did not show any sequelae of former infection.
All 6 blood-culture bottles (3 BACTEC aerobic plus/
F and 3 BACTEC anaerobic lytic/F; Becton Dickinson, 
Sparks, MD, USA.) were positive with gram-positive cocci 
in chains. The isolate grew as transparent α-hemolytic col-
onies (0.5- to 1-mm diameter) on sheep blood Columbia 
agar after an incubation of 24 h at 35°C in 4% CO2-enriched 
atmosphere. The biochemical identifi cation system API 20 
Strep (bioMérieux, Lyon, France) was used to attempt the 
identifi cation. The numerical profi le was 4241450, indi-
cating S. sanguinis (95% similarity). Agglutination with 
Lancefi eld antisera (Streptokit, bioMérieux) was nega-
tive for groups A, B, C, D, F, and G. Antimicrobial MICs 
were determined with Etest (AB Biodisk, Solna, Sweden). 
Results were interpreted according the available Clinical 
Laboratory Standard Institute (CLSI, formerly NCCLS) 
criteria (7) (Table).
The genetic sequence of the 16S rRNA was determined 
by a capillary sequence analyzer (ABI 3130 XL DNA An-
alyzer, Applied Biosystems (Foster City, CA, USA) and 
compared with the nucleotide sequences in GenBank. Of 
>1,000 bp in the 16S rRNA sequence, only 2 differed from 
the previously published S. sinensis HKU4 (AF432856) 
(1), a sequence identical to that of HKU5 (AF432855) and 
HKU6 (AF432857) (4). Results were positive for identify-
ing the superoxid dismutase (sodA) (primer from reference 
8) and RNA polymerase β-subunit (rpoB) (9) housekeep-
ing gene sequences. Concerning sodA, for >404 bp there 
was 97.3% homology with the positive S. sinensis strain 
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AY386220 (9) and only 2 bp differences in >286 bp (99.3% 
homology) with the S. sinensis strain EF451825. Concern-
ing rpoB, 485 bp were identical over 516 nt sequences 
(94% homology) of the S. sinensis strain AF199923 (9).
Conclusions
We report a case outside Hong Kong of infective en-
docarditis caused by a strain of S. sinensis. Information on 
this novel pathogen has been published for 3 Chinese pa-
tients (2–4). Ours is the fourth published case worldwide. 
Because the original S. sinensis (1) is most closely related 
to our strain, we believe that our isolate belongs to that spe-
cies. The close relationship of the sequence of our strain to 
the referential sodA and rpoB gene sequences also identi-
fi es our Geneva strain as S. sinensis. We have submitted the 
sodA and rpoB sequencing results to GenBank (accession 
nos. EF585234 and EF591041, respectively).
A 16S rRNA sequence with only 3 base differences 
from HKU4 had been detected by a German group in the 
aortic valve of another patient (GenBank accession no. 
AY049738, unpub. data), and other sequences have been 
reported by a French group (EF371928, unpub. data) and a 
British group (AY386220, unpub. data). We do not know 
more about these cases. Our Geneva strain differed only in 
2 nt bases from the HKU4 strain (on positions 43 and 48) 
and only in 1 base (position 66) from the German sequence, 
whereas it is identical with the French sequence. This might 
suggest the emergence of a European strain of S. sinensis. 
From a clinical point of view, all reported patients (1,4) 
had an underlying chronic rheumatic heart disease of the 
mitral valve as the major risk factor. Only l patient had a 
preceding tooth extraction (4), like our patient with teeth 
abscesses. No other infections besides endocarditis caused 
by S. sinensis have been described thus far in humans or in 
animals. All previously reported patients were successfully 
treated by i.v. penicillin G or ampicillin for 4 weeks (com-
bined therapy with gentamicin during the fi rst 2 weeks) 
without necessity for surgical intervention. In light of other 
streptococcal endocarditic recommendations (10,11) and 
reported experiences with S. sinensis (4), our 6 weeks of 
antimicrobial drug treatment was probably excessive. The 
elective mitral valve replacement was indicated because of 
the severity of the preexisting regurgitation.
In conclusion, our case outside Hong Kong confi rms 
that S. sinensis causes endocarditis throughout the world. 
Like other viridans streptococci, S. sinensis might be part 
of the human oral fl ora. The real number of cases is prob-
ably underestimated because commercial kits misidentify 
S. sinensis as S. intermedius or S. anginosus (1). With ad-
equate sequencing technology, further reports may indicate 
the real prevalence of this emerging pathogen.
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